San Diego biotech vies with giants to develop physical, pharmacological, and gene-editing approaches to fighting the disease.
San Diego-based ViaCyte says that its portfolio of stem-cell derived therapies includes first-in-category, first-in-class products that represent major advances toward a functional cure for type 1 diabetes (T1D) and other chronic diseases. In June, ViaCyte closed a Series D financing with a final tranche of $45 million that brought the total raised in the round to more than $115 million. [ViaCyte]
Funding the development of functional cure therapies for T1D is the intended use of proceeds for ViaCyte’s latest financing, which it closed in June. ViaCyte closed the Series D with a final tranche of $45 million, bringing the total raised in this round to more than $115 million . . .
